UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, has raised $20 million from the sale of common stock and will use some of the funding to boost its research into a Covid-19 vaccine. The company’s vaccine, known as Terra CoV-2 and produced from a spike protein licensed from the National Institutes of Health, has gone through one round of clinical trials, to date, and a second phase is in the works. The vaccine has been shown to produce protective immunity to the coronavirus in mice.
“We are in scale-up phase right now,” Oragenics president and CEO Dr. Alan Joslyn said. “Our goal is to have an immediate intense response, which will hopefully lead to the development of a single-dose vaccine.”Learn more about Biotech Firm Raises $20 Million, Sees Progress on COVID-19 Vaccine.